Leading the Way in Life Science Technologies

GEN Exclusives

More »

Assay Tutorials

More »
Apr 15, 2009 (Vol. 29, No. 8)

Breaking HTS Cell-Based Assay Bottlenecks

New Tool Designed to Provide High-Efficiency Transfections with any Molecule in all Cell Types

  • Transfecting Cell Lines

    Click Image To Enlarge +
    Figure 2. Using the MaxCyte STX, HEK 293 and Vero cells were transfected with eGFP plasmid DNA.

    The MaxCyte STX can transfect with high efficiency essentially any mammalian cell line, differentiated human primary cell type, or human stem cell of interest to HTS studies. The data in the Table is representative of the cell types that have been efficiently transfected using the MaxCyte STX.

    All electroporations use plasmid DNA encoding green fluorescent protein (GFP) as a marker of transfection efficiency (expressed as the percentage of GFP-positive cells at 24–48 hours post-transfection). Cell viability for the same period is the percentage of cells excluding propidium iodide (PI). For many cells, transfection efficiency and viability are often >90%. Figure 2 shows Vero and HEK293 cells that have been transfected with GFP plasmid; bright field and fluorescent images are shown 24 hours after electroporation with the MaxCyte STX.

    The MaxCyte STX can also be used to transfect primary cells and stem cells, which are difficult to transfect by other methods. These types of cells are increasingly being considered for use in cell-based assays because they are more biologically relevant than cell lines.

  • Click Image To Enlarge +

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »